Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163417 | 1.00 | GRIN1 (0.41) | GRIN1GRIN2BEPHX1CES2CES1 | |
| SCHEMBL4079497 | 1.00 | GRIN1 (0.41) | GRIN1GRIN2BEPHX1CES2CES1 | |
| SCHEMBL532572 | 0.98 | GRIN1 (0.39) | GRIN1GRIN2BEPHX1CES2CES1 | |
| SCHEMBL4743867 | 0.93 | — | — | |
| SCHEMBL730203 | 0.87 | HDAC2 (0.34) | GRIN1GRIN2B | |
| SCHEMBL543403 | 0.87 | — | — | |
| SCHEMBL761935 | 0.80 | CES2 (0.38) | GRIN1GRIN2BEPHX1CES2CES1 | |
| SCHEMBL6360578 | 0.79 | EPHX2 (0.33) | — | |
| SCHEMBL23749603 | 0.78 | HTT (0.47) | GRIN1GRIN2BCES2CES1GRIK1 | |
| SCHEMBL9743609 | 0.78 | HTT (0.47) | GRIN1GRIN2BCES2CES1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-7500895-B2 | Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device | SEIKO EPSON CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060127563-A1 | Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device | SEIKO EPSON CORPORATION (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20050287392-A1 | Organic electroluminescent device, method for producing the same, and electronic apparatus | SEIKO EPSON CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| US-5554496-A | SHIELDING AN ANTICURL BACKING LAYER FROM PROCESSING SOLUTIONS; HYDROPHOBIC POLYMER; QUICK-DRYING, NONCRACKING | FUJI PHOTO FILM CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | PRPH, BDNF, GAP43 | GRIN1 114/4885GRIN2B 170/4885EPHX1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.